• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MedAlliance closes enrollment for sirolimus-coated balloon trial

August 13, 2021 By Sean Whooley

MedAlliance SELUTION SLRMedAlliance announced today that it closed patient enrollment for its clinical trial of the Selution SLR 018 BLF drug-eluting balloon.

Nyon, Switzerland–based MedAlliance designed its Selution SLR 018 BLF for the treatment of patients with disease below the knee. The company touts Selution SLR as the first device of its kind to receive an “innovative device designation” from the FDA.

Selution SLR includes unique micro-reservoirs made of biodegradable polymer intermixed with sirolimus. The micro-reservoirs provide a controlled and permanent release of the drug for up to 90 days, while MedAlliance’s CAT (cell-adherent technology) allows microdeposits to coat the balloons and adhere to the vessel lumen when delivered through an angioplasty balloon.

The Pristine clinical trial will investigate the safety and efficacy of treatment with the sirolimus-coated balloon in infrainguinal artero-occlusive disease TASC C and D over 12 months in a group of 75 patients from Singapore suffering from chronic ischemia that threatens the lower extremities, according to a news release.

Pristine serves as a follow-up registry for the Prestige trial, which showed sustained benefits for up to one year. MedAlliance said it expects to observe a similar benefit in the Pristine trial from a larger, real-world population.

Selution SLR holds CE mark, having garnered approval in February 2020 for treating peripheral artery disease, then again in May 2020 for coronary artery disease. The company expects to begin an FDA investigational device exemption trial later this year.

“This is an important study for MedAlliance,” MedAlliance president & CEO Jeffrey B. Jump said in the release. “Our innovative technology has demonstrated safety and efficacy in diseases below the knee in highly complex patients, as seen in the Prestige trial. We expect similar observations in the Pristine registry. This is particularly encouraging as, to date, no other BLF has demonstrated efficacy in this complex patient population. ”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: drug-eluting balloon, MedAlliance

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS